TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02252211
Drug: DS-8895a 3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients received infusions with \^89Zr-Df-DS-8895a at a dose of 0.2 mg/kg on Day 1, DS-8895a at a dose of 3 mg/kg on Days 8 and 22, and \^89Zr-Df-DS-8895a at a dose of 3 mg/kg on Day 36. Patients who responded or had stable disease per RECIST version 1.1 at the Day 50 restaging may have continued to receive biweekly treatment with DS-8895a until disease progression.
Study: NCT02252211
Drug: DS-8895a 10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients were to receive infusions with \^89Zr-Df-DS-8895a at a dose of 0.2 mg/kg on Day 1, DS-8895a at a dose of 10 mg/kg on Days 8 and 22, and \^89Zr-Df-DS-8895a at a dose of 10 mg/kg on Day 36. Patients who responded or had stable disease per RECIST version 1.1 at the Day 50 restaging may have continued to receive biweekly treatment with DS-8895a until disease progression.
Study: NCT05487508
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (NaCl 0.9%)
Study: NCT01590277
Drug: Active Ethanol
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Target BrAC of 0.1% reached over 30 minutes and then clamped to maintain this dose for an additional 60 minutes. This dose is equivalent to consuming approximately 5 drinks. Administered over a total of 90 minutes.
Study: NCT01002859
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Injection of NaCl solution
Study: NCT01590277
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control: no alcohol, administered for a total of 90 minutes.
Study: NCT01590277
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control: no iomazenil, administered for a total of 10 minutes
Study: NCT02556021
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, tablet, once daily, oral administration for up to 4 weeks
Study: NCT02824276
Drug: Placebo Treatment
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactose (Appearance and Weight-matched placebo capsules)
Study: NCT03165045
Drug: Spiolto® Respimat®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 weeks
Study: NCT05274945
Drug: consolidation chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 cycles of FOLFOX or CAPOX
Study: NCT06369675
Drug: MOB015B vehicle
Normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical formulation
Study: NCT01829802
Drug: TDF/FTC (or 3TC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dose combination of Tenofovir 300 mg/Emtricitabine 200 mg or Tenofovir 300 mg/Lamivudine 300 mg plus Ritonavir Boosted Atazanavir 300/100mg given once a day
Study: NCT00218855
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg x 2 mg tablets escalating to 200 mg x 2 until plateau phase. Maintenance 100 mg x 2 until relapse. This procedure is repeated by first relapse.
Study: NCT01350960
Drug: SPC5001
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 weekly SC injections
Study: NCT01350960
Drug: Saline 0.9%
Normalized name: CVS Saline 0.9% Nasal Mist
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 weekly SC injections
Study: NCT04470492
Drug: Medical Management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be treated with conventional medication for 3 months.
Study: NCT02523664
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: effects of hydrocortisone on memory while fMRI
Study: NCT02523664
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02822339
Drug: BAY987517
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z12-030)
Study: NCT02023164
Drug: JDP-205 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine, 10mg/mL; a single 1.0 mL injection via intravenous (IV) push over a period of \~2 minutes
Study: NCT02665234
Drug: Placebo Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle Ophthalmic Solution
Study: NCT03017248
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% normal saline
Study: NCT02145923
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy will be performed according to protocols ICE and BEAM (standard scheme)
Study: NCT01725152
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral suspension, given in 3 divided doses
Study: NCT01795898
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl transdermal patches releasing 12.5 microgram of fentanyl will be applied for 3 days. The patches will be replaced every 3 days (Day 3, 7 and 10).
Study: NCT04386616
Drug: MSTT1041A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received one intravenous (IV) infusion of MSTT1041A 700 milligrams (mg) on Day 1. A second IV dose of MSTT1041A 350 mg was given on Day 15 if the participant remained hospitalized with a requirement for supplemental oxygen.
Study: NCT04386616
Drug: MSTT1041A-matched Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received up to 2 intravenous infusions of MSTT1041A-matched placebo.
Study: NCT04386616
Drug: UTTR1147A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received one intravenous (IV) infusion of UTTR1147A 90 micrograms/kilogram body weight (μg/kg) on Day 1. A second IV dose of UTTR1147A 90 μg/kg was given on Day 15 if the participant remained hospitalized with a requirement for supplemental oxygen.
Study: NCT03301766
Drug: standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drugs prescribed at the discretion of the treating physician (acetaminophen, NSAIDs, muscle relaxants, etc)
Study: NCT03301766
Drug: Non-medicated patch
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: non-medicated patch
Study: NCT01037504
Drug: AZD5423
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suspension for nebulisation, inhaled. Each subject will receive an inhaled dose of AZD5423 or placebo once daily for 14 days. Starting dose as determined from SAD study and with up to 4 dose escalations not exceeding AstraZeneca pre-defined exposure limits.
Study: NCT01037504
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for nebulisation, inhaled. Each subject will receive an inhaled dose of AZD5423 or placebo once daily for 14 days.
Study: NCT04386616
Drug: UTTR1147A-matched Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received up to 2 intravenous infusions of UTTR1147A-matched placebo.
Study: NCT04514237
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets
Study: NCT02640846
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Norepinephrine will be given to the patient due to septic shock. After the inclusion we will change the dose of Norepinephrine to achieve 3 different MAP-levels, 60 mmHg, 75 mmHg and 90 mmHg.
Study: NCT01236612
Drug: Malarone treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: When thick smear positive, of ar day 21 after challenge, all volunteers will be treated with malarone.
Study: NCT00782418
Drug: Comparator: Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% osmitrol in two 60 mcL subcutaneous doses 120 minutes apart, followed by either HGC or GGI. After a 14 day washout period two additional 60 mcL doses will be administered, followed by HCG or GGI.
Study: NCT04393584
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: d1 Leucovorin 200 mg/m² every two weeks
Study: NCT04137276
Drug: vitamin C, vitamin B1
Approvals — FDA: no, EMA: no, PMDA: no
Description: vitamin C 1,5 g/6 hours IV + thiamine 200 mg/12 hours for 3 days
Study: NCT01337531
Drug: Gonal-F, Fostimon
Approvals — FDA: no, EMA: no, PMDA: no
Description: dosage form
Study: NCT01337531
Drug: Gonal-F, Fostimon
Approvals — FDA: no, EMA: no, PMDA: no
Description: injection, daily, 10-15 days
Study: NCT01178853
Drug: Warfarin 5mg + Rosuvastatin 40 mg once daily (QD)
Normalized name: lisinopril
DrugBank: Lisinopril (DB00722)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Warfarin 5mg + Rosuvastatin 40 mg once daily (QD)
Study: NCT02870790
Drug: TDF/FTC
Approvals — FDA: no, EMA: no, PMDA: no
Description: one pill daily
Study: NCT00048594
Drug: Comparator: placebo (unspecified)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04087421
Drug: Glycerol OBA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal suppository. Stimulates the rectum and softens and loosens stool.
Study: NCT01438749
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose
Study: NCT01438749
Drug: RO4917838
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single doses (3 dose levels)
Study: NCT01515995
Drug: Nebulized magnesium sulfate
Normalized name: Hydra-Neb
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg albuterol in 22 ml of magnesium sulfate solution (880 mg) via nebulizer over one hour~Versus~15 mg albuterol in 22 ml of normal saline via nebulizer over one hour
Study: NCT01163253
Drug: CP-690,550
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg oral BID
Study: NCT01163253
Drug: CP-690,550
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg oral BID
Study: NCT00005986
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00543569
Drug: Corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids were administered as a 500 to 1000 mg intravenous bolus on Day 0 and a 125 to 250 mg methylprednisone (or equivalent oral/intravenous corticosteroid dose) on Day 1. Oral prednisone was to be tapered per protocol.
Study: NCT00905307
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT06531447
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Every 21 days 4 cycles
Study: NCT06531447
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Every 21 days 4 cycles
Study: NCT01682837
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 sachet mixed with 250 ml water given at breakfast and dinner, for a total of 2 sachets/day, for 4 weeks
Study: NCT00898677
Drug: Comparator: Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo to rizatriptan
Study: NCT04121728
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo is presented in the form of capsules of identical mass, color and shape to those of the study product. It is composed of lactose, the excipients present in Symfona® 120 mg and colorants. The dosage is identical to that of the investigational product.
Study: NCT04697758
Drug: AXT107 0.1 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravitreal injection of AXT107 0.1 mg/eye
Study: NCT04697758
Drug: AXT107 0.25 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravitreal injection of AXT107 0.25 mg/eye
Study: NCT04697758
Drug: AXT107 0.5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravitreal injection of AXT107 0.5 mg/eye
Study: NCT01316926
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine Hydrochloride 25 miligrams (mg) tablet with controlled release (Paxil CR) manufactured by GlaxoSmithKline Inc. - Mississauga - Canada (test formulation)
Study: NCT01316926
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine Hydrochloride 25 mg tablets with controlled release (Paxil CR) manufactured by SmithKline Beecham (Cork) Limited - Cidra - Puerto Rico (reference formulation)
Study: NCT01629329
Drug: Aspirin, Acetaminophen, Caffeine pills
Approvals — FDA: no, EMA: no, PMDA: no
Description: One time dose of 2 pills each containing acetaminophen 250mg, aspirin 250mg and caffeine 65mg in each tablet. Simultaneous administration of placebo(5ml of saline administered IV)
Study: NCT03871647
Drug: Beta blocker
Normalized name: Beta blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: perioperative beta blockers
Study: NCT01365000
Drug: NKTR118 Formulation 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dose, 25 mg
Study: NCT01365000
Drug: NKTR118 Formulation 2
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dose, 25 mg
Study: NCT01365000
Drug: NKTR118 Formulation 3
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dose, 25 mg
Study: NCT00148733
Drug: Zinc
Normalized name: Zinc
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dissolvable zinc tablet 10 mg elemental zinc per day for infants 20 mg elemental zinc per day for children 12 to 35 months
Study: NCT00590018
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone taper (100mg/m2/day --\> 25mg/m2/day) over 5 days intravenously.
Study: NCT00590018
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for 5 days intravenously.
Study: NCT03016442
Drug: Dinoprostone
Normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10 mg of dinoprostone in a hydrogel insert is placed high in the vaginal fornix. İt is placed for 12 hours.It is a controlled release formulation which has been found to release dinoprostone in vivo at a rate of approximately 0.3 mg/hr.
Study: NCT03523832
Drug: Celecoxib and Pregabaline
Normalized name: amlodipine and celecoxib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose versus repetition dose
Study: NCT00000271
Drug: Desipramine
Normalized name: Desipramine
DrugBank: Desipramine (DB01151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants were treated with desipramine, up to 300 mg per day, or matching placebo. All participants received weekly individual manual-guided relapse prevention therapy.
Study: NCT00131040
Drug: Aprotinin
Normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01519245
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: A total volume of 70mL of normal saline poured over the heart as a 'cardiac bath' prior to sternotomy closure near the end of surgery. Total duration of immersion is approximately 10 minutes, until mediastinal chest tubes are connected to suction. Identical in appearance to the trial drug, and is visually indistinguishable.
Study: NCT00136747
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04436224
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous analgesia using fentanyl in ICU patients with non-mechanical ventilation(NS 40ML+ fentanyl 0.5mg, IV-Pump)
Study: NCT02222220
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01410188
Drug: OPA-6566
Normalized name: O-PHTHALALDEHYDE 22 g in 4000 mL TOPICAL LIQUID [Safe OPA]
Approvals — FDA: no, EMA: no, PMDA: no
Description: OPA-6566, 2 dosing schedules (one drop once per day for 2 weeks and twice per day for 2 weeks)
Study: NCT00710424
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: containing peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient.
Study: NCT00178490
Drug: High blood pressure treatment
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants who are identified as having high blood pressure will be given by a pediatric nephrologist a 12-month treatment plan for their high blood pressure. The treatment plan will include a combination of diet, weight loss, increased exercise, and if needed, blood pressure medication. Participants receiving medication treatment will be treated with a calcium channel blocker and/or ACE inhibitor.
Study: NCT04638790
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25 mg/m2 i.v. day 1,15 for ABVD/AVD
Study: NCT01410188
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, 2 dosing schedules (one drop once per day for 2 weeks and twice per day for 2 weeks)
Study: NCT00647777
Drug: Zyprexa® Tablets 5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5mg, single dose fed
Study: NCT00952289
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablets were administered as oral doses in the same manner as active drug.
Study: NCT04638790
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg/m2 i.v. day 1 for EACODD-14
Study: NCT04638790
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 650 mg/m2 i.v. day 1
Study: NCT00645398
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo capsules taken orally, 2 capsules BID for 13 weeks (1 week titration phase + 12 weeks fixed-dose phase).
Study: NCT02517372
Drug: CRD007
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02586636
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given as concurrent treatment in one of the two treatment periods. Placebo treatment dose is fixed at one tablet twice daily (to match the dosing pattern of omeprazole) for four weeks duration. Omeprazole, in our study, is used as an OCT1 inhibitor, and we hypothesise that this will reduce an individual's maximum tolerated dose of metformin during concurrent treatment. This will be compared to the other treatment period in which concurrent treatment is a placebo, and therefore, the maximum tolerated dose of metformin would not be affected.
Study: NCT00011765
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01474330
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule
Study: NCT00605241
Drug: GSK598809
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug
Study: NCT00820768
Drug: ABI-010
Normalized name: PICEA ABIES WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17-AAG and ABI-007
Study: NCT03746860
Drug: Tablet, Dispersible
Normalized name: TABLET, DISPERSIBLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet/day with 12 SQ-HDM per lyo-tablet
Study: NCT03809182
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intraoperative fentanyl was given in case of 25% increment in the blood pressure and/or heart rate in comparison to baseline (previous anesthesia induction).
Study: NCT01225640
Drug: PNU-100480
Normalized name: Trichophyton antigen 1000 PNU/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg twice daily (BID) for 14 days
Study: NCT01225640
Drug: PNU-100480
Normalized name: Trichophyton antigen 1000 PNU/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg once daily (QD) for 14 days
Study: NCT01734161
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects randomized to placebo receive 50cc normal saline
Study: NCT03375112
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patient will be brought to the block room within 30 minutes of arriving in recovery. An ultrasound probe will be placed to the skin and a blunt needle will be touched to the patient's skin in the area that a fascia iliaca compartment block would be performed. The patient will then be transported back to recovery.
Study: NCT00332748
Drug: Oral Taxane
Normalized name: acetaminophen / oxycodone hydrochloride Oral Capsule [Taxadone]
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03921268
Drug: AZD1402
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD1402 (PRS-060) is presented as a solution and dry powder for oral inhalation and belongs to a new class of therapeutics, Anticalin® proteins, which are modified lipocalins. AZD1402 is an inhaled IL-4Rα antagonist, which is being developed as controller therapy for asthma.
Study: NCT02876055
Drug: Local Infiltration Analgesia (LIA)
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of local anesthetic into the peri-articular tissues and intra-articular capsule in a systematic approach for orthopedic surgery
Study: NCT00777491
Drug: induction 5-fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400mg/m\^2 administered as a 24-hour infusion on days 1,2,3, and 15,16,17.
Study: NCT04160468
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a single IV infusion of placebo in addition to SoCA selected by the investigator.
Study: NCT03987620
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo
Study: NCT01790737
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03440216
Drug: blood sampling
Normalized name: TERUFLEX Blood with Diversion Blood Sampling Arm Anticoagulant CPD with OPTISOL Red Cell Preservative for Collection of 450mL of Blood KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: * temocillin: blood sampling every day for 7 days~* ceftriaxone: blood sampling 12h after administration for 7 days~* meropenem: blood sampling at 1h, 3h, 5h and 8h after initiation of the administration at days 1 and 2; one sampling at 8h on days 3 to 7
Study: NCT03440216
Drug: Tissue sampling (lung)
Normalized name: tissue respiratory factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sampling of tissue (lung) when possible during treatment for measurement of the content in antibiotic (temocillin, ceftriaxone, or meropenem, depending on the drug received by the patient)
Study: NCT03859986
Drug: ALX-101 Gel Vehicle
Normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALX-101 Gel Vehicle
Study: NCT03859986
Drug: ALX-101 Gel 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALX-101 Gel 5%
Study: NCT02597023
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pill with inert excipient, 1 time/day
Study: NCT00484250
Drug: metronidazole,doxycycline
Approvals — FDA: no, EMA: no, PMDA: no